Skip to main content

Table 1 Demographic patient data

From: Transesophageal vs. intracardiac echocardiographic screening in patients undergoing atrial fibrillation ablation with uninterrupted rivaroxaban

 

TEE group

ICE group

p-value

Paroxysmal

71 (61,7%)

196 (90,3%)

<0.001

Persistent

38 (33%)

18 (8,3%)

<0.001

Long-standing persistent

6 (5,3%)

3 (1,4%)

0.042

Age, years

57.4 ± 11.5

67.6 ± 8.3

<0.001

BMI

28.6 ± 4.5

29.7 ± 4.6

0.044

Coronary artery disease

27 (23.5%)

1 (0.4%)

<0.001

Hypertension

78 (67.8%)

210 (96.8%)

<0.001

Diabetes mellitus

11 (9.6%)

65 (29.9%)

<0.001

Congestive heart failure

16 (13.9%)

22 (10.1%)

0.312

Previous stroke or TIA

1 (0.8%)

0 (0%)

0.951

Left atrial size, mm

41.9 ± 6.2

43.4 ± 3.7

0.006

LV EF, %

58.9 ± 8.3

60.2 ± 7.7

0.194

Creatinine clearance, ml/min

108.81 ± 32.76

112.06 ± 24.05

0.092

CHA2DS2-VASc score

2.09 ± 0.91

2.46 ± 0.61

0.048

0

23 (20%)

1 (0.4%)

<0.001

1

28 (24.3%)

2 (0.9%)

<0.001

≥2

64 (55.7%)

214 (98.6%)

<0.001

HAS-BLED

0.85 ± 0.89

0.96 ± 0.84

0.071

  1. Data are presented as mean ± SD
  2. AF atrial fibrillation, BMI body mass index, TIA transient ischemic attack, TEE transesophageal echocardiogram, ICE intracardiac echocardiography, LV EF left ventricular ejection fraction
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us